From Paula Weisenberger, MD, Medical Oncologist and Hematologist at OHC
October 29, 2020
One of every five breast cancers are HER2-positive breast cancers. This type tends to grow and spread faster than other breast cancers but are much more likely to respond to treatments that target the HER2 protein.
A recent study reported that women diagnosed with metastatic HER2-positive breast cancer lived longer if they were eligible for surgery to remove the primary tumor. At OHC, we’re concerned about women whose cancer can’t be removed surgically. That’s why we’re excited to offer a clinical trial for these patients where surgery isn’t an option. In this trial, we’re evaluating the drug tucatinib combined with the drug T-DM1 (ado-trastuzumab emtansine) to see if it works better than T-DM1 alone.
Tucatinib binds to the part of the HER2 protein that is inside the cancer cell and prevents it from sending signals that promote cell growth. T-DM1, a chemotherapy drug, directly attacks the HER2-positive cancer cells to shrink tumors and extend survival in women with metastatic breast cancer.
This two-pronged attack could be a significant option for patients if the results are as promising as we hope.
My colleagues and I at OHC are committed to providing cancer patients with new, innovative treatments, so when one treatment isn’t an option, we have other treatments – often more advanced – to offer patients. This is an example of our relentless pursuit to find the best treatments and make them available to our patients.
To learn more about the breast cancer experts at OHC and how they’re fighting cancer through advanced treatments and clinical trials, or to request a second opinion, visit ohcare.com or call 1-888-649-4800.Comments (0)